valsartan has been researched along with Cardio-Renal Syndrome in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Chai, HT; Chen, CH; Chen, YL; Chiang, JY; Sung, PH; Yang, CC; Yip, HK | 1 |
| Campillejo, RD; de Vinuesa, EG; Gervasini, G; Robles, NR; Valladares, J; Villa, J | 1 |
| Bao, Q; Kang, L; Li, G; Li, R; Li, Y; Liu, T; Rong, K; Shao, S; Suo, Y; Tse, G; Yuan, M; Zhang, Y | 1 |
| Chen, CH; Chen, YL; Chen, YT; Huang, TH; Li, YC; Shao, PL; Sun, CK; Yang, CC; Yip, HK | 1 |
| Chen, J; Hu, YJ; Peng, DF; Tang, SY | 1 |
| Chen, J; Hu, YJ; Huang, Q; Peng, DF; Peng, X; Tang, SY | 1 |
| Gu, Y; Liu, XY; Wang, H; Wu, J; Zhang, MJ; Zhu, PF | 1 |
1 trial(s) available for valsartan and Cardio-Renal Syndrome
| Article | Year |
|---|---|
Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS).
Topics: Aged; Aged, 80 and over; Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardio-Renal Syndrome; Creatinine; Cystatin C; Drug Combinations; Female; Glomerular Filtration Rate; Hemoglobins; Humans; Male; Retrospective Studies; Valsartan | 2021 |
6 other study(ies) available for valsartan and Cardio-Renal Syndrome
| Article | Year |
|---|---|
Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
Topics: Aminobutyrates; Animals; Apoptosis; Biphenyl Compounds; Cardio-Renal Syndrome; Cardiovascular Agents; Drug Combinations; Fibrosis; Humans; Inflammation; Kidney; Male; Myocardium; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Simendan; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Renal protective effects and mechanisms of the angiotensin receptor-neprilysin inhibitor LCZ696 in mice with cardiorenal syndrome.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardio-Renal Syndrome; Cell Line; Drug Combinations; Kidney; Male; Mice; Mice, Inbred C57BL; Protective Agents; Rats; Valsartan | 2021 |
The therapeutic impact of entresto on protecting against cardiorenal syndrome-associated renal damage in rats on high protein diet.
Topics: Aminobutyrates; Animals; Apoptosis; Autophagy; Biomarkers; Biphenyl Compounds; Blood Urea Nitrogen; Cardio-Renal Syndrome; Creatinine; Diet, High-Protein; Drug Combinations; Fibrosis; Gene Expression Regulation; Kidney; Male; Mitochondria; Myocardium; NADPH Oxidases; Oxidative Stress; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 2; Tetrazoles; Valsartan | 2019 |
Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats.
Topics: Angiotensin II; Animals; Atorvastatin; Benzazepines; C-Reactive Protein; Cardio-Renal Syndrome; Case-Control Studies; Drug Synergism; Heptanoic Acids; Lipids; Male; Natriuretic Peptide, Brain; Proteinuria; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2015 |
Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS).
Topics: Aged; Antihypertensive Agents; Atorvastatin; Benzazepines; C-Reactive Protein; Cardio-Renal Syndrome; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Natriuretic Peptide, Brain; Protective Agents; Valsartan | 2015 |
Valsartan attenuates cardiac and renal hypertrophy in rats with experimental cardiorenal syndrome possibly through down-regulating galectin-3 signaling.
Topics: Animals; Cardio-Renal Syndrome; Cardiomegaly; Disease Models, Animal; Down-Regulation; Echocardiography; Galectin 3; Glomerular Filtration Rate; Heart; Heart Failure; Kidney; Male; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Signal Transduction; Valsartan | 2016 |